DMK Pharmaceuticals Corporation (DMKPQ)

Market Cap	247.30K
Revenue (ttm)	3.62M
Net Income (ttm)	-22.23M
Shares Out	7.07M
EPS (ttm)	-9.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,598
Open	n/a
Previous Close	0.0350
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About DMKPQ

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other aller...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 11
• Stock Exchange: OTCMKTS
• Ticker Symbol: DMKPQ

Financial Performance

In 2022, DMKPQ's revenue was $4.76 million, an increase of 115.34% compared to the previous year's $2.21 million. Losses were -$26.48 million, -42.22% less than in 2021.